thank Well, you, Tracey.
these the Obesity effective turning is receptor cardiovascular the diabetes, and have highly of top of now the been weight see issue, impact XX. our chronic weight loss therapies moving a management incredible agonists approved to of and a public and of across conditions, transformed public including And cardiometabolic to disease. global Slide health It's from number our have the apnea to and GLP-X industry health programs impressive impact the sleep potential loss. innovation how
market with an With projected sales. $XXX receive is in treatment to agonists, XX receptor anticipated generate billion million GLP-X over current to estimated the
Moving XX. Slide to
With the with ranging amount also therapies, substantial of seen muscle XX%. weight extraordinary that XX% amount a lean to receptor also current is from of there's lost, the GLP-X loss
and regain therapy of disproportionately fat of leading body accompanies a to composition strength lean mass lean occurs worse leading weight the and use associated significant stopping widespread weakness being that of the an there's with mass, loss unhealthy increased muscle these more the to and that than therapies, gain. regained weight awareness when reduced With this
Beyond a insulin improving role main plays strength energy and increasing metabolism, significant metabolic and basal metabolic muscle organ the in mobility, is in glucose uptake sensitivity. rate,
when Given weight to added believe loss selective reducing the receptor toxicities, leading of to management. myostatin agonists GLP-X healthy additional introducing without overall sustainable profile muscle critical the health, in role to by that muscle can and mass their approach blocking enhance our the lean we plays highly
the XX tirzepatide change of study, randomized with weight tirzepatide. study The in period in to To expected XX. Slide proof-of-concept area the from this illustrates our Phase tirzepatide, figure from II time. be weeks the what in Moving time can to represents assessment is the study corresponding green EMBRAZE, and efficacy illustrate body the first over shaded the percent SURMOUNT-X
mass, of XX seen, weight loss of weeks. this is to deepen our there's blocking XX, through Approximately skeletal loss address the of body to amount by even over be of can course XX% week impressive As weight an the of that XX% to we master area selective lean muscle. of we highly regulator an can weight myostatin, that approach XX% believe continues
to amount of healthier mass management. loss, sustainable lean weight potentially mass the loss can lean the By change and for preserving treatment it lead and and muscle weight loss paradigm reducing
Slide to moving Now XX.
have lean be about what for healthy strict And kilogram can what who mass to needed were to rest respect Well, confined does men muscle bed a lean amount week from assessed a DEXA clinical lost of as benefit? scans. preserving and X is meaningful impact? study with of So by insights a to young gained mass mean
and, additive loss adults an year, Remarkably, sensitivity in mass be in baseline. the profound. in to lean other just lean per X GLP-X begin to mass can of XX importantly, lose of group of of of XX% compared effect in therapy the resulted associated per with exercise a over receptor capacity decrease Considering strength mass and that subsets significant equally leg X% kilogram loss age strength, decrease lean decade, XX% with this insulin to
in plus Slide goals or we EMBRAZE, placebo designed Phase our we had when adults. obese tirzepatide to overweight to in study tirzepatide comparing key to several With randomized mind proof-of-concept II moving plus Now XX. respect apitegromab EMBRAZE,
with at portion week we tirzepatide, need XX DEXA to to for we'll measured recognizing the steepest to First, loss highly of program. our selected scans that XX point this mass, XX of loss muscle to since week approach assess weight can as with preserving the was We our assess the respect week curve selective at believe amount time reduce of myostatin. we the as blocking by lean SRK-XXX
of loss magnitude to from men, the As benefit reducing a looking in X since and proof-of-concept the kilogram to in mass our the we study we mass X kilograms by XX% to we're amount study, lean of clinical help of believe lean clinical meaningful lean into X will shape loss X meaningful mass regarding by a -- can of Extrapolating translate to preserve effect kilograms, improvement. lean which muscle matters. mass, trends for X thinking every of between young assuming XX%,
one associated such Second, on can TGF-beta with approach, toxicity selective that ligand not be introduce to tirzepatide of our demonstrate based combine safely active. other goals any we was additive and can blocking as our that
see respect are time. expecting loss we XX, to at weight to with at this comparable week weight loss Third,
of can on line performed data These stopping additional next our results have based the after with in an at this forward nonclinical look stopping important scan built fat to question. weeks believe DEXA we the treatment X not assess Fourth, will to and we regain data, tirzepatide part quarter. top blunt we that be associated sharing
or Fifth, included power we such did for patients exploratory measures, to subsets show as the endpoints and a endpoints. of hemoglobin we study exploratory AXc enrich these significance with but functional proof-of-concept statistical study, also as not
data and And then have SRK-XXX, detailed in for to to cardiometabolic highly all clinical is subject identify the for the selective the disorders. of inform We'll setting a of finally, an important for development the opportunity of experience subgroups obesity. us review gain anti-myostatin to designed key our goal help EMBRAZE
of schedule, experience We've momentum already shown provides ahead this our us with SRK-XXX deliver ability EMBRAZE for and program. great to
with to to excited preserve are greater nonclinical GLP-X parameters such anti-ActRII XX. further receptor mass regain program agonist and And lean been glucose, respect as comparison potency with mass a seen once a in demonstrated demonstrating to blood improve we an metabolic mass, Slide and generated can the mass we've therapy, we've our in we the increase of in stopping SRK-XXX, gain with fat after the that's fat antibody. direct fat Moving very we data date in can reduction lean with
the to featured in later profile been to best-in-class year. we conferences Overall, and which bringing key has data for XXXX, clinic SRK-XXX scientific a suggests at SRK-XXX, this look forward
XX. -- Moving to study highly at and, of advancing the In lean of loss mass ambition therapy. receptor to path by problem therapies IND, of conducting a address specifically study have innovative, selective GLP-X transform the same proof proof-of-concept apitegromab we current of EMBRAZE our with therapies, treatment taken anti-myostatin for highly a summary, to our loss to associated with the time, anti-myostatin Slide portfolio novel important with SRK-XXX cardiometabolic emerging parallel industry-leading weight selective the indications designed agonist with
readout XXXX, from the of quarter the for and SRK-XXX milestones important X strategy filing and of to next we EMBRAZE in top resulted This look forward the data IND QX. the in line has in
moving Rock. closing, for XXXX be and XX. year will In Slide transformative to a Scholar
with and We a well potential start. those continue youngest rare as expand for We've to in those treatment MAA reach the submit SMA to apitegromab, EU are and to starting SMA we in disorders. a muscle-targeted new to way the submitted of therapy, our to QX living to other option with the neuromuscular the off work the in March, follow in U.S. our XXXX, EU on with in we're for in globally, great bring BLA apitegromab to the preparations our on in We're to January. track U.S. in
Scholar. We are the of exciting franchise, progress and expand forward achieving apitegromab of We Overall, to and on very reporting our starting SMA. advance look on as we key XXXX toward establishing the for neuromuscular to a a with very, commercialize development cardiometabolic our year threshold our milestones programs. drive
for the operator, remarks. call up We'll the that prepared questions. closes And now open
